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Dengue outbreaks have increased in size and frequen-
cy in Australia, and transfusion-transmitted dengue poses a 
risk to transfusion safety. Using whole blood samples col-
lected during the large 2008–2009 dengue epidemic, we 
estimated the risk for a dengue-infectious blood donation as 
≈1 in 7,146 (range 2,218–50,021).
Dengue causes >50 million infections per year world-wide; however, the true incidence is expected to be 
higher given that asymptomatic infection is possible (1). 
Dengue virus types 1–4 (DENV-1–4) are emerging or re-
emerging in many regions of the world (1,2), including 
Australia (3). One of the largest epidemics in at least 50 
years occurred in Queensland, Australia, during 2008–
2009, with separate outbreaks in Cairns (and surrounding 
regions; DENV-2, DENV-3; 2008–2009), Innisfail (DENV-
4; 2009), and Townsville (DENV-1, DENV-3; 2009), total-
ing >1,000 confirmed clinical cases (3).
Infection with DENVs poses a risk for transfusion 
safety, and 5 cases of transfusion-transmitted dengue have 
been reported (4,5). In addition, DENV RNA has been de-
tected in asymptomatic blood donors from areas to which 
dengue is endemic (6–8). Given the absence of an ap-
proved blood screening test for dengue in Australia, man-
aging transfusion-transmission risk focuses on identify-
ing donors at risk for exposure and temporarily excluding 
them from donating fresh blood components (erythrocytes, 
platelets, and clinical plasma) (referred to here as dengue 
management strategy) (9). Plasma collection for fraction-
ation can continue because the process of manufacturing 
concentrates inactivates the virus (10). This approach as-
sists with meeting an expanding demand for intravenous Ig 
but may result in fresh component losses and be associated 
with considerable cost.
Risk to the blood supply correlates with asymptomatic 
donor viremia; understanding the rate of dengue subclini-
cal infection in countries to which it is not endemic and 
local northern Queensland seroprevalence is necessary for 
assessing this risk. We examined dengue seroprevalence 
rates in Australian donors during this epidemic; used these 
data to estimate the subclinical infection rate, population 
prevalence, and associated transfusion-transmission risk; 
and estimated the economic effect of this epidemic to the 
Australian Red Cross Blood Service (Blood Service).
The Study
Whole blood samples collected during the 2008–2009 
dengue epidemic were tested for DENV IgM by ELISA 
(Dengue IgM Capture ELISA; Panbio, Brisbane, QLD, 
Australia). All reactive samples were tested with a second 
ELISA (Anti-Dengue IgM ELISA; Standard Diagnostics 
Inc., Giheung-gu, South Korea) and by the Public Health 
Virology Laboratory at Queensland Health Forensic and 
Scientific Services (QHFSS) (11). Serologic evidence of 
recent exposure (presence of DENV IgM) was observed in 
12 (0.22%) donors (Table 1). Of the 8 DENV IgM–positive 
samples that were examined for type specificity, 7 (88%) 
were DENV-3 specific, which was the dominant type dur-
ing the epidemic (3).
We used these IgM seroprevalence rates to estimate 
the rate of subclinical dengue infection (online Techni-
cal Appendix, wwwnc.cdc.gov/EID/article/19/5/12-1664-
Techapp1.pdf). We estimated 168–921 subclinical cases 
(clinical:subclinical ratio 1.0:0.59; range 0.18–1.0) in 
Cairns, the city where the epidemic was centered. Our esti-
mate was toward the lower end of that observed in dengue-
endemic areas (12,13) but higher than that estimated dur-
ing a DENV-2 outbreak in Charters Towers (14), which 
probably reflects the different methods used in the respec-
tive studies.
Selected samples were tested for DENV IgG by ELISA 
(Dengue IgG Indirect ELISA; Panbio). All reactive sam-
ples were tested at QHFSS. Serologic evidence of previous 
exposure (presence of DENV IgG) was influenced overall 
by donor location (p<0.05) and age (p<0.05). The propor-
tion of the northern Queensland donor population with 
DENV IgG was 9.43% (95% CI 7.98%–10.89%), and this 
proportion increased with age (Table 2), which indicates 
cumulative previous exposure. The proportion of Mel-
bourne (control area with no dengue activity) donors with 
DENV IgG was 6.78% (95% CI 4.48%–9.09%); however, 
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no change was observed with age (Table 2), demonstrating 
no cumulative exposure. Previous exposure in Melbourne 
was surprisingly high; these persons may have been ex-
posed during travel to dengue-endemic areas (subsequent 
follow-up demonstrated 94% reported travel to countries to 
which dengue may be endemic).
The proportion of donors with DENV IgG did not 
change from the beginning to the end of the outbreaks in 
Cairns and Townsville, nor in northern Queensland as a 
whole (Table 2), which suggests that the epidemic was not 
of a scale to result in a change in population seroprevalence. 
This study was powered to detect a change in incidence of 
at least 10%; small changes might have been missed, which 
would be difficult to detect through such studies.
We used our seroprevalence data along with donation 
frequencies to estimate the risk of collecting a dengue-in-
fectious donation, based on published models (9,15) (on-
line Technical Appendix). Using this model, the risk of col-
lecting a dengue-infectious donation in Cairns during the 
epidemic was ≈1 in 7,146 (range 2,218–50,021) (Figure). 
These estimates are similar to those obtained by using a 
published probabilistic model (9) revised to incorporate the 
outbreak specific subclinical infection rate reported herein, 
which predicts the risk to be ≈1 in 9,303 (range 3,092–
32,344) donations in Cairns. Because both methods derive 
estimates within comparable ranges, it would appear valid 
to use the revised probabilistic model as a predictive risk 
estimator during future outbreaks.
The dengue management strategy used during the epi-
demic cost the Blood Service ≈1–3.8 million Australian dol-
lars (2009 terms). This estimate is publically available and 
was based on: the number of donations affected by the den-
gue management strategy, collection targets for 2009, costs 
associated with whole blood collections, additional costs to 
meet national targets, transportation costs to meet demand 
in affected regions, and additional waste costs. An offset for 
any plasma obtained through a whole blood donation (used 
for fractionation) was included in selected estimates.
Conclusions
Subclinical dengue infection rates vary by population, 
specific outbreak, and area examined (12,14). We demon-
strate that the clinical to subclinical infection rate during 
the 2008–2009 dengue epidemic in northern Queensland, 
where dengue occurs seasonally, was toward the lower end 
of that observed in dengue-endemic countries (12,13). This 
observation, together with our data suggesting that the inci-
dence of dengue in the northern Queensland population did 
not change from the beginning to the end of the epidemic, 
suggests the control and clinical management of dengue 
during this epidemic was comprehensive.
We also estimated that the risk of collecting a dengue-
infectious blood donation in Cairns during the epidemic was 
≈1 in 7,146 (range 2,218–50,021). Given these risks, the in-
creasing need for plasma in Australia, and the absence of a 
screening test for blood donations in Australia, the continu-
ation of the dengue management strategy during future out-
breaks is warranted. However, this strategy may have added 
strain on the inventory available to meet clinical demand for 
fresh blood components and was associated with a cost to 
the Blood Service of >1 million Australian dollars. Although 
this strategy is a necessary precaution to maintain safety, 
alternative approaches may exist, such as implementation 
of a suitable screening test (were one available) or patho-
gen reduction technology (a process designed to inactivate 
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Table 1. Serologic evidence of recent dengue exposure by dengue virus IgM in blood donors, northern Queensland, Australia, 2008–
2009 epidemic 
Location 
Donors 
 
Donations 
No. samples Reactive samples, no. (% [95% CI]) No. samples Reactive samples, no. (% [95% CI]) 
North Queensland 5,453 12 (0.22 [0.10–0.34])  10,026 13 (0.13 [0.06–0.20]) 
Cairns 2,416 8 (0.33 [0.10–0.56])  5,051 9 (0.18 [0.06–0.29]) 
Townsville 3,037 4 (0.13 [0.00–0.26])  4,975 4 (0.08 [0.00–0.16]) 
 
Table 2. Prevalence of dengue virus IgG in the blood donor 
population, northern Queensland, Australia 
Variable 
No. 
samples Reactive, no. (% [95% CI]) 
Northern Queensland 1,548 146 (9.43 [7.98–10.89]) 
 Age group, y   
  <40 567 18 (3.17 [1.73–4.62]) 
  40–60 742 70 (9.43 [7.33–11.54]) 
  >60 239 58 (24.27 [18.83–29.70]) 
 Outbreak   
  Start 788 72 (9.14 [7.13–11.15]) 
  End 760 74 (9.74 [7.63–11.84]) 
Cairns 738 53 (7.18 [5.32–9.04]) 
 Age group, y   
  <40 271 5 (1.85 [0.24–3.45]) 
  40–60 360 26 (7.22 [4.55–9.90]) 
  >60 107 22 (20.56 [12.90–28.22]) 
 Outbreak   
  Start 384 31 (8.07 [5.35–10.80]) 
  End 354 22 (6.21 [3.70–8.73]) 
Townsville 810 93 (11.48 [9.29–13.68]) 
 Age group, y   
  <40 296 13 (4.39 [2.06–6.73]) 
  40–60 382 44 (11.52 [8.32–14.72]) 
  >60 132 36 (27.27 [19.68–34.87]) 
 Outbreak   
  Start 404 41 (10.15 [7.20–13.09]) 
  End 406 52 (12.81 [9.5–16.066]) 
Melbourne 457 31 (6.78 [4.48–9.09]) 
 Age group, y   
  <40 151 11 (7.28 [3.14–11.43]) 
  40–60 215 16 (7.44 [3.93–10.95]) 
  >60 91 4 (4.40 [0.18–8.61]) 
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pathogens in blood products), which may offer a similar lev-
el of safety but be more cost effective. With dengue becom-
ing increasingly common in Australia (3) and the world (1), 
these alternative approaches may be needed in the future.
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Figure. Risk of collecting a dengue-infectious blood donation, 
northern Queensland, Australia, 2008–2009 epidemic. Estimated 
risk calculated for Cairns (A) and Townsville (B).
